Drug
Temsirolimus clinical trials
Also written Torisel and CCI-779.
- studies test it
- 177
- open now
- 4
- in phase 3
- 9
- first study started
- 2000
Keep track of what changes. Save the temsirolimus studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
176 studies that test it; most in 2009 (34)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 4 |
| 2002 | 3 |
| 2003 | 6 |
| 2004 | 10 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 12 |
| 2008 | 20 |
| 2009 | 34 |
| 2010 | 31 |
| 2011 | 13 |
| 2012 | 13 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 86
- Phase 2
- 99
- Phase 3
- 9
- Phase 4
- 1
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 157
National Cancer Institute (NCI) (61) · M.D. Anderson Cancer Center (13) · Pfizer (7) · Washington University School of Medicine (6) · Wyeth is now a wholly owned subsidiary of Pfizer (5) · Canadian Cancer Trials Group (3) · Puma Biotechnology, Inc. (3) · St. Jude Children's Research Hospital (2)
Often tested with
Tested in the same studies.
Bevacizumab (17) · Sorafenib (11) · Cixutumumab (7) · Sunitinib (6) · Doxorubicin (6) · Irinotecan (5) · Cisplatin (5) · Pazopanib (5)
Studies
Open first, then newest update. How each study uses temsirolimus is read from its arms, and is right about nine times in ten.
Testing it · 177
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as Temsirolimus
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Temsirolimus
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the KneeRecruitingPhase 3Mercator MedSystems, Inc.NCT04433572Written as Temsirolimus
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceRecruitingEarly Phase 1Miller Children's & Women's Hospital Long BeachNCT02446431Written as Temsirolimus
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02567435Written as Temsirolimus
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02389309Written as Temsirolimus
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01375829Written as Temsirolimus
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00977574Written as Temsirolimus
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsCompletedPhase 2St. Jude Children's Research HospitalNCT01946529Written as temsirolimus
- Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT02215720Written as Temsirolimus
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT01396408Written as Temsirolimus
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01087554Written as Temsirolimus
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerCompletedPhase 3National Cancer Institute (NCI)NCT00980460Written as Temsirolimus
- Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGGTerminatedEarly Phase 1Nader SanaiNCT05773326Written as Temsirolimus
- Temsirolimus in Combination With Metformin in Patients With Advanced CancersTerminatedPhase 1M.D. Anderson Cancer CenterNCT01529593Written as Temsirolimus
- Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal RevascularizationTerminatedPhase 2Mercator MedSystems, Inc.NCT03942601Written as Temsirolimus
- Temsirolimus for Relapsed/Refractory Hodgkin's LymphomaTerminatedPhase 2Loyola UniversityNCT00838955Written as Temsirolimus
- NCT Neuro Master Match - N²M² (NOA-20)CompletedPhase 1/2University Hospital HeidelbergNCT03158389Written as Temsirolimus
- Phase II Study of Alternating Sunitinib and TemsirolimusCompletedPhase 2Dartmouth-Hitchcock Medical CenterNCT01517243Written as Temsirolimus
- Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursCompletedPhase 1Canadian Cancer Trials GroupNCT02343718Written as Temsirolimus
See all 177 studies that test temsirolimus →
Given in every arm · 14 — temsirolimus is usual care beside what is tested
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01187199Written as Temsirolimus
- Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic CancerTerminatedPhase 1M.D. Anderson Cancer CenterNCT03203525Written as Temsirolimus
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedPhase 1AstraZenecaNCT00600496Written as Temsirolimus
- Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedPhase 1M.D. Anderson Cancer CenterNCT01552434Written as Temsirolimus
- Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck CancerWithdrawnNot applicableSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT01326468Written as Temsirolimus
- Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine GliomaCompletedPhase 1M.D. Anderson Cancer CenterNCT02420613Written as Temsirolimus
- Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasCompletedPhase 1Andrew B Lassman, MDNCT02238496Written as Temsirolimus
- Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy MalesCompletedPhase 1CelgeneNCT01712828Written as Temsirolimus
- Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial CancerCompletedPhase 2National Cancer Institute (NCI)NCT00729586Written as Temsirolimus
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00329719Written as Temsirolimus
- Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)TerminatedPhase 1/2Western Regional Medical CenterNCT02423954Written as Temsirolimus
- Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous TherapyCompletedPhase 2National Cancer Institute (NCI)NCT01256385Written as Temsirolimus
- Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00112736Written as temsirolimus
- Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS MutationsCompletedPhase 2Vejle HospitalNCT00827684Written as Temsirolimus
As the comparator · 2 — what is tested is compared with temsirolimus
- Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)Status unknownPhase 2Mercator MedSystems, Inc.NCT02908035Written as Temsirolimus
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal TumorsStatus unknownNot applicableUniversity Hospital, GrenobleNCT03571438Written as Temsirolimus
Codes
What other systems call temsirolimus · ClinicalTrials.gg INT004196
- MeSH (NLM) C401859temsirolimusConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 624KN6GM2TTEMSIROLIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 657797Confirmed FDA, Wikidata
- Wikidata Q7699074temsirolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1844TemsirolimusOne source FDA
- DrugBank DB06287One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C401859 | temsirolimus | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 624KN6GM2T | TEMSIROLIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 657797 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7699074 | temsirolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1844 | Temsirolimus | One source FDA |
| DrugBank | DB06287 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.